--- title: 2024, another great year for drug approvals description: 2024 drug approvals highlight breakthroughs in oncology, rare diseases, and precision medicine, showcasing innovation in drug discovery and patient care. image: https://www.euretos.com/hubfs/LI%20main%20image.png --- [![Euretos - Data-driven disease insight](https://www.euretos.com/hs-fs/hubfs/Negative-logo-1.png?width=207&height=49&name=Negative-logo-1.png "Euretos - Data-driven disease insight")](https://www.euretos.com) [![Euretos - Data-driven disease insight](https://www.euretos.com/hs-fs/hubfs/logo-1.png?width=207&height=48&name=logo-1.png "Euretos - Data-driven disease insight")](https://www.euretos.com) - [Disease Atlas](https://www.euretos.com/disease-atlas) - [Get Access](https://www.euretos.com/pricing) - [Methodology](https://www.euretos.com/disease-atlas-methodology) - [Blog](https://www.euretos.com/blog) Menu [![Login](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/7609166/interactive-167498164057.png)](https://www.euretos.com/hs/cta/wi/redirect?encryptedPayload=AVxigLJboEA5uwpeUUETy1mC4EV%2FNyu6ENdRuP%2FqOc0%2BAt%2FxK29fqAUfrvzlsWzLxlp0GlofLY5gjGtvjG9YBxCLujiWlNTNm98ST6nmXNPciT%2FYZHjtHJGN0Mx6%2Fbm3B9%2FulEL9Eml2DQHdWQR5IpnB9A7fXhQZlrDvnuP1EMDoAEwh&webInteractiveContentId=167498164057&portalId=7609166) [![Contact Us](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/7609166/interactive-167498163994.png)](https://www.euretos.com/hs/cta/wi/redirect?encryptedPayload=AVxigLLo7WfQBVPuCYNkfWv3C1fBsLoEjXs252RjKe8Uu8WNaiKknIIR1pAS7RZpDY5gW9Ey9AKi8HDmZC0mwVNk2nr1biadAnzSCOafXkzKARy%2F86D9r9ef9XsK1MmkrMF2pga4sZCOTR2yWwxP7nc05fDCeV04pUimcGGpze5r8%2FSb%2FXwGGMgl3g%3D%3D&webInteractiveContentId=167498163994&portalId=7609166) [![Euretos - Data-driven disease insight](https://www.euretos.com/hs-fs/hubfs/logo-1.png?width=207&height=48&name=logo-1.png "Euretos - Data-driven disease insight")](https://www.euretos.com) [![Login](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/7609166/interactive-167498164057.png)](https://www.euretos.com/hs/cta/wi/redirect?encryptedPayload=AVxigLJboEA5uwpeUUETy1mC4EV%2FNyu6ENdRuP%2FqOc0%2BAt%2FxK29fqAUfrvzlsWzLxlp0GlofLY5gjGtvjG9YBxCLujiWlNTNm98ST6nmXNPciT%2FYZHjtHJGN0Mx6%2Fbm3B9%2FulEL9Eml2DQHdWQR5IpnB9A7fXhQZlrDvnuP1EMDoAEwh&webInteractiveContentId=167498164057&portalId=7609166) Home Features Pricing Menu Sluit x [![Euretos - Data-driven disease insight](https://www.euretos.com/hs-fs/hubfs/Negative-logo-1.png?width=207&height=49&name=Negative-logo-1.png "Euretos - Data-driven disease insight")](https://www.euretos.com) - [Disease Atlas](https://www.euretos.com/disease-atlas) - [Get Access](https://www.euretos.com/pricing) - [Methodology](https://www.euretos.com/disease-atlas-methodology) - [Blog](https://www.euretos.com/blog) - [Disease Atlas](https://www.euretos.com/disease-atlas) - [Get Access](https://www.euretos.com/pricing) - [Methodology](https://www.euretos.com/disease-atlas-methodology) - [Blog](https://www.euretos.com/blog) # 2024, another great year for drug approvals As we close out 2024, it’s remarkable to look back at what has been another successful year for translational science and drug discovery. With [**50 novel drug approvals**](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024?utm_source=chatgpt.com), the pace of innovation has remained strong. ![Drug Appovalspng](https://www.euretos.com/hs-fs/hubfs/Drug%20Appovalspng.png?width=749&height=334&name=Drug%20Appovalspng.png)These approvals highlight a continuing evolution in precision medicine, novel modalities, and our collective commitment to tackling some of the world’s most challenging diseases.  At Euretos, we specialize in empowering researchers with the tools to accelerate target discovery, assessment, and safety evaluation. Reflecting on the trends in 2024’s approvals, several themes stand out: **Diversity in Therapeutic Areas** This year’s approvals have targeted a wide range of conditions, showcasing the breadth of unmet medical needs being addressed. Leading therapeutic areas include: - **Oncology**: A standout category with approvals for **non-small cell lung cancer (NSCLC)** and **unresectable cancers**, reflecting advancements in targeted therapies. - **Rare Diseases**: Treatments for **familial chylomicronemia syndrome**, **Niemann-Pick disease**, and **classic congenital adrenal hyperplasia** illustrate a growing focus on orphan drugs, aligning with regulatory incentives to drive innovation in underserved areas. - **Cystic Fibrosis**: A new triple-combination therapy approval marked another leap forward for individuals living with this chronic condition. ![3drug combination CF](https://www.euretos.com/hs-fs/hubfs/3drug%20combination%20CF.png?width=1281&height=475&name=3drug%20combination%20CF.png) The variety demonstrates the industry’s commitment to addressing both prevalent and niche diseases, fueled by improved understanding of molecular pathways and advanced data analytics. **Spotlight on Novel Modalities** Innovative drug modalities are shaping the therapeutic landscape: - **Multi-Component Therapies**: Approvals like **vanzacaftor/tezacaftor/deutivacaftor** for cystic fibrosis underscore the value of combination strategies that target multiple aspects of disease biology. - **Biologics**: Antibodies and RNA-targeting therapies, such as **olezarsen**, continue to rise as powerful tools for disease modulation. - **Precision Medicine**: Many approvals, particularly in oncology, highlight the shift toward highly personalized treatments driven by biomarker data. These advances emphasize the importance of integrating multi-omics data and computational tools in the discovery process—a core capability we offer to our partners. **Notable Trends** - **Accelerated Approval Pipelines:** Nearly half of this year’s approvals were supported by breakthrough designations or priority reviews, demonstrating the FDA’s dedication to expediting life-saving therapies. ![FDA Fast track](https://www.euretos.com/hs-fs/hubfs/FDA%20Fast%20track.png?width=994&height=309&name=FDA%20Fast%20track.png) - **Monthly Peaks in Approvals:** Approvals peaked in **March** and **April**, correlating with major medical conferences—an indicator of how real-world evidence and collaborations are driving regulatory readiness. - **Focus on Patient-Centric Outcomes:** From gene therapies to advanced biologics, patient outcomes and quality of life were clearly front and center in many new therapies. This signals a broader shift in how success is measured, going beyond efficacy to include safety and convenience.![EuretosLaptop](https://www.euretos.com/hs-fs/hubfs/EuretosLaptop.png?width=529&height=357&name=EuretosLaptop.png) **Looking Ahead** 2024 has been a testament to the power of data-driven research and collaboration. At Euretos, we are proud to support the scientific community in uncovering novel targets, de-risking drug candidates, and optimizing safety profiles. By implementing new advancements in AI, machine learning, and computational biology, 2025 promises to push the boundaries of drug discovery even further. Stay tuned for exciting announcements! We extend our congratulations to all the teams behind this year’s successes and look forward to continuing this important work together. Let’s build on this momentum and transform even more lives in the year ahead. Subscribe #### Euretos Newsletter Subscribe to our mailing list and receive our quarterly updates! Read our [Terms and Conditions](https://www.euretos.com/euretos-ai-platform-terms-and-conditions-of-use) ![](https://www.euretos.com/hubfs/Vector%20(4).svg) ## Data-driven disease insights ![](https://www.euretos.com/hubfs/Euretoslogofooterv4.png) #### Subscribe to our Newsletter Keep up with our latest news and events. Sign up for our newsletter. #### Resources - [News](https://www.euretos.com/blog) - [Help center](https://askeuretos.freshdesk.com/support/home) - [Support Request](https://www.euretos.com/submit-support-request) #### Euretos - [About us](https://www.euretos.com/about) - [Contact](https://www.euretos.com/contact-form) #### Follow us [![](https://www.euretos.com/hs-fs/hubfs/Linkedin.png?width=22&name=Linkedin.png)](https://twitter.com/euretos) [![](https://www.euretos.com/hs-fs/hubfs/Twitter.png?width=26&name=Twitter.png)](https://twitter.com/euretos) © 2024 Euretos. - [T&Cs - Services](https://www.euretos.com/euretos-ai-platform-terms-and-conditions-for-services) - [T&Cs - AI Platform](https://www.euretos.com/euretos-ai-platform-terms-and-conditions-of-use) - [Privacy policy](https://www.euretos.com/euretos-privacy-policy) ![](https://px.ads.linkedin.com/collect/?pid=3328428&conversionId=4680788&fmt=gif)